{"filing":{"accession_number":"0001193125-26-387351","cik":"0001816736","ticker":"IRON","company_name":"Disc Medicine, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-09","primary_document":"iron-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/iron-20260909.htm"},"events":[{"id":32571,"run_id":29929,"accession_number":"0001193125-26-387351","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Disc Medicine announced initial Phase 2 clinical trial results for DISC-3405 in polycythemia vera patients, demonstrating dose-proportional pharmacokinetics, hematocrit control, significant reduction in phlebotomy events (mean decreased from 4.0 to 0.6, p\u003c0.0001), and a favorable safety profile. This represents a material clinical milestone for the company's drug development pipeline.","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35771,"accession_number":"0001193125-26-387351","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Disc Medicine announced initial Phase 2 clinical trial results for DISC-3405 in polycythemia vera patients, demonstrating efficacy in reducing phlebotomy events, controlling hematocrit, and improving symptoms. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the earnings_release category (which applies to financial results) nor any other specific event type. The disclosure represents a significant operational/strategic advancement in the company's drug development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:49:40.886386+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35772,"accession_number":"0001193125-26-387351","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Disc Medicine announced initial Phase 2 clinical trial results for DISC-3405 in polycythemia vera patients, demonstrating dose-proportional pharmacokinetics, hematocrit control, significant reduction in phlebotomy events (mean decreased from 4.0 to 0.6, p\u003c0.0001), and favorable safety profile. This is a material clinical milestone for a clinical-stage biopharmaceutical company advancing a novel therapeutic candidate toward potential pivotal development, affecting investor assessment of pipeline progress and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:49:40.886386+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35771,"accession_number":"0001193125-26-387351","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Disc Medicine announced initial Phase 2 clinical trial results for DISC-3405 in polycythemia vera patients, demonstrating efficacy in reducing phlebotomy events, controlling hematocrit, and improving symptoms. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the earnings_release category (which applies to financial results) nor any other specific event type. The disclosure represents a significant operational/strategic advancement in the company's drug development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:49:40.886386+00:00","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-09-10"},{"id":35772,"accession_number":"0001193125-26-387351","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Disc Medicine announced initial Phase 2 clinical trial results for DISC-3405 in polycythemia vera patients, demonstrating dose-proportional pharmacokinetics, hematocrit control, significant reduction in phlebotomy events (mean decreased from 4.0 to 0.6, p\u003c0.0001), and favorable safety profile. This is a material clinical milestone for a clinical-stage biopharmaceutical company advancing a novel therapeutic candidate toward potential pivotal development, affecting investor assessment of pipeline progress and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:49:40.886386+00:00","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-09-10"}]}